Low-density lipoprotein cholesterol and coronary heart disease: The importance of reaching target goals with statin therapy - Commentary

Journal of Family Practice

Volumn 58, Issue 11 SUPPL., 2009, Pages

  Tóth, Peter P ^a,b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b Preventive Cardiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

ARTICLE; BLOOD; CORONARY ARTERY DISEASE; FEMALE; HUMAN; LIFESTYLE; MALE; RISK FACTOR; TREATMENT OUTCOME;

CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; LIPIDS; MALE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84858172085     PISSN: 00943509     EISSN: 15337294     Source Type: Journal    
DOI: None     Document Type: Note

References (16)

1. American Heart Association. Heart Disease & Stroke Statistics - 2009 Update. Dallas, TX: American Heart Association; 2009.
2. Kuller L, Borhani N, Furberg C, et al. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am J Epidemiol. 1994;139:1164-1179. (Pubitemid 24184410)
3. Ingelsson E, Sullivan LM, Murabito JM, et al. Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes. 2007;56:1718-1726. (Pubitemid 46842616)
4. Lewis SJ, Fox KM, Grandy S, for the SHIELD Study Group. Self-reported diagnosis of heart disease: results from the SHIELD study. Int J Clin Pract. 2009;63:726-734.
5. Cannon CP, Braunwald E, McCabe CH, et al, for the Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
6. de Lemos JA, Blazing MA, Wiviott SD, et al, for the A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z trial. JAMA. 2004;292:1307-1316. (Pubitemid 39223221)
7. LaRosa JC, Grundy SM, Kastelein JJP, et al, on behalf of the Treating to New Targets (TNT) Steering Committee and Investigators. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study). Am J Cardiol. 2007;100:747-752. (Pubitemid 47271930)
8. Eaton CB, Galliher JM, McBride PE, et al. Family physician's knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: a national research network (NRN) survey. J Am Board Fam Med. 2006;19:46-53. (Pubitemid 44046993)
9. Gislason GH, Rasmussen JN, Abildstrøm SZ, et al. Long-term compliance with beta-blockers, angiotensin- converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27:1153-1158.
10. Baessler A, Fischer M, Huf V, et al. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates. Int J Cardiol. 2005;101:293-298. (Pubitemid 40637627)
11. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147-1152. (Pubitemid 40720739)
12. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol. 2006;97(suppl):44C-51C.
13. Toth PP, Harper C, Jacobson T. Clinical characterization and molecular mechanisms in statin myopathy. Expert Rev Cardiovasc Ther. 2008;6:955-969.
14. Alsheikh-Ali AA, Maddukuri PV, Han H, et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer. J Am Coll Cardiol. 2007;50:409-418. (Pubitemid 47096680)
15. Sheridan S, Pignone M, Mulrow C. Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med. 2003;18:1039-1052. (Pubitemid 38091400)
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.